Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03834220 · ClinicalTrials.gov registry record · Phase 2
Basket Trial in Solid Tumors Harboring a Fusion of FGFR1, FGFR2 or FGFR3- (FUZE Clinical Trial)
A Phase 2 study, sponsored by Debiopharm International.
- Terminated
- Registry status
- Phase 2
- Development phase
- 63
- Enrollment target
NCT03834220 is a Phase 2 study that was terminated before completion, run by Debiopharm International. The registered enrollment target is 63 participants.
The verdict
NCT03834220, a Phase 2 study, was terminated before completion, sponsored by Debiopharm International.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 63 participants
- Enrollment target
Study Summary
The primary objective of this study is to assess the efficacy of Debio 1347 in terms of objective response rate (ORR) in participants with solid tumors harboring fibroblast growth factor receptor (FGFR)1-3 gene fusion/rearrangement.
Interventions
- DRUG Debio 1347
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2019-03-22 |
| Est. Completion | 2022-01-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03834220
The ClinicalTrials.gov registry entry for NCT03834220 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 63 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Debiopharm International, which has 30 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Debio 1347 is the first listed.
NCT03834220 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03834220 about?
NCT03834220 is a clinical study titled "Basket Trial in Solid Tumors Harboring a Fusion of FGFR1, FGFR2 or FGFR3- (FUZE Clinical Trial)". The primary objective of this study is to assess the efficacy of Debio 1347 in terms of objective response rate (ORR) in participants with solid tumors harboring fibroblast growth factor receptor (FGFR)1-3 gene fusion/rearrangement.
What is the current status of trial NCT03834220?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 63 participants. The study started on 2019-03-22. Estimated completion is 2022-01-04.
What interventions are being tested in trial NCT03834220?
The interventions under investigation include: Debio 1347 (DRUG).
Who is sponsoring clinical trial NCT03834220?
This trial is sponsored by Debiopharm International, which has 30 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.